Biotherapeutic immunogenicity profile is determined by a lot of products and the risk factors associated with patients that may affect the observed incidence and clinical

If new scientific knowledge to be produced more efficiently and applied to the advancement of health, human safety should be more effectively dealt with in

recombinant pharmaceutical proteins expressed in the culture of hair follicles can be secreted into the medium to improve the homogeneity of the product and to

High concentration antibody formulation development for subcutaneous administration the remains challenging. More recently, a precipitation-redissolution method is proposed to prepare a suspension or deposition of

In the field of biological drug development, high throughput (HT) technology is the key to identifying the most promising therapeutic candidates in an efficient manner